Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood (2011) 117 (22): 5827–5834.

https://doi.org/10.1182/blood-2010-10-312603

Published: 2011

Journal Articles

A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia

Lisa M. Arfons, MD, Mark H. Kirschbaum, MD, Timothy W. Synold, PharmD, Hillard M. Lazarus, MD, Tamila L. Kindwall-Keller, DO, Mary J. Laughlin, MD, Maureen G. Conlan, MD, Joe Seroogy, Larry Doyle, Brenda W. Cooper, MD

Blood (2008) 112 (11): 4038.

https://doi.org/10.1182/blood.V112.11.4038.4038

Published: 2008

Journal Articles

The Novel Histone Deacetylase Inhibitor, LBH589, Induces Expression of DNA Damage Response Genes and Apoptosis in Ph-Acute Lymphoblastic Leukemia Cells.

Scuto Anna, PhD, Mark H. Kirschbaum, MD, Peter Atadja, Agnes Juhasz, Vinod Pullarkat, MD, Ravi Bhatia, MD, Stephen J. Forman, MD, Yun Yen, MD, PhD, Richard Jove, PhD

Blood (2007) 110 (11): 2796.

https://doi.org/10.1182/blood.V110.11.2796.2796

Published: 2007

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.

Mark H. Kirschbaum, MD, Bryan H. Goldman, MS, Jasmine M. Zain, MD, James R. Cook, MD, PhD, Lisa M. Rimsza, MD, Stephen J. Forman, MD, Richard I. Fisher, MD

Blood (2007) 110 (11): 2574.

https://doi.org/10.1182/blood.V110.11.2574.2574

Published: 2007

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

Mark H. Kirschbaum, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Vinod Pullarkat, MD, Auayporn P. Nademanee, MD, Maria L. Delioukina, MD, Bernadette Pulone, RN, Deron Matsuoka, BS, Paul Frankel, PhD, Zwiebel A. James, MD, Stephen J. Forman, MD, Edward Newman, PhD, David Gandara, MD

Blood (2007) 110 (11): 2568.

https://doi.org/10.1182/blood.V110.11.2568.2568

Published: 2007

Journal Articles

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

Harry P. Erba, MD, PhD, Kenneth J. Kopecky, PhD, Mark H. Kirschbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD, Cheryl L. Willman, MD, Marilyn L. Slovak, PhD, Holly M. Gundacker, MA, Frederick R. Appelbaum, MD

Blood (2007) 110 (11): 440.

https://doi.org/10.1182/blood.V110.11.440.440

Published: 2007

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark H. Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, John Wright, MD, Bernadette Pulone, RN, Amalia Rincon, Paul Frankel, PhD, Stephen J. Forman, MD, Edward Newman, PhD

Blood (2007) 110 (11): 891.

https://doi.org/10.1182/blood.V110.11.891.891

Published: 2007

Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators

Blood (2006) 108 (11): 2469.

https://doi.org/10.1182/blood.V108.11.2469.2469

Published: 2006

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

NARROW

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia

The Novel Histone Deacetylase Inhibitor, LBH589, Induces Expression of DNA Damage Response Genes and Apoptosis in Ph-Acute Lymphoblastic Leukemia Cells.

Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study.

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only